JPH03169817A - Blood pressure regulating agent containing 1alpha-hydroxyvitamin d3 compounds - Google Patents
Blood pressure regulating agent containing 1alpha-hydroxyvitamin d3 compoundsInfo
- Publication number
- JPH03169817A JPH03169817A JP24470590A JP24470590A JPH03169817A JP H03169817 A JPH03169817 A JP H03169817A JP 24470590 A JP24470590 A JP 24470590A JP 24470590 A JP24470590 A JP 24470590A JP H03169817 A JPH03169817 A JP H03169817A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxyvitamin
- 1alpha
- blood pressure
- pressure regulating
- regulating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036772 blood pressure Effects 0.000 title claims abstract description 12
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 title claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 title abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 239000007900 aqueous suspension Substances 0.000 abstract description 2
- 239000007891 compressed tablet Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 235000019441 ethanol Nutrition 0.000 abstract description 2
- 239000007902 hard capsule Substances 0.000 abstract description 2
- 239000007905 soft elastic gelatin capsule Substances 0.000 abstract description 2
- 239000002511 suppository base Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 2
- 244000299461 Theobroma cacao Species 0.000 abstract 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 abstract 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 abstract 1
- 235000014121 butter Nutrition 0.000 abstract 1
- 235000001046 cacaotero Nutrition 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 239000007901 soft capsule Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000015225 Primary intrahepatic lithiasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、１α−ヒドロキシビタミンＤ３類を含有する
血圧調節剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a blood pressure regulator containing 1α-hydroxyvitamin D3.
近年、デルカ（Ｄｅ Ｌｕｃａ ）等及びコデイツク（
Ｋｏｄｉｅｋ）等の一連の研究の結果、ビタミンＤ３の
生体内活性物質が工α，２５−ジヒドロキシビタミンＤ
（以下１α．２５− （ＯＨ） −Ｄ３と略３２
称する）であり、また■α位の水酸基の存在がその生物
活性の発現には必須であることが明らかにされた。以後
この活性型の工α， ２５ （Ｏ Ｈ ）２−Ｄ ３の
類似体、例えば１α−ヒドロキシビタミンＤ３（以下１
α一（ＯＨ）−Ｄ３と略称する）、１α．２４−ジヒド
ロキシビタミンＤ３ （以下１α，２４（ＯＨ） −
Ｄ３と略称する）など多くの１α一２
ヒドロキシビタミンＤ３類が合成され、１α．２５（Ｏ
Ｈ） ２ Ｄ ３とともにそのビタミンＤ様生物活
性が注目されており、１α−（ＯＨ）−Ｄ３は慢性腎不
全、副甲状腺機能低下症．ビタミンＤ抵抗性クル病・骨
軟化症におけるビタミンＤ代謝異常を伴う諸症状（低カ
ルシウム血症，テタニ骨痛，骨病変等）の改善に適応さ
れている。In recent years, De Luca et al. and Kodytsk (
As a result of a series of studies by Kodiek et al.
(hereinafter abbreviated as 1α.25-(OH)-D3), and it was revealed that the presence of a hydroxyl group at the α-position is essential for the expression of its biological activity. Hereinafter, analogues of this active form of enzyme α,25(OH)2-D3, such as 1α-hydroxyvitamin D3 (hereinafter referred to as 1
abbreviated as α-(OH)-D3), 1α. 24-dihydroxyvitamin D3 (hereinafter 1α,24(OH) −
Many 1α-2 hydroxyvitamin D3s such as 1α-2 hydroxyvitamin D3 are synthesized, including 1α. 25(O
H) 2 Along with D3, its vitamin D-like biological activity has attracted attention, and 1α-(OH)-D3 is associated with chronic renal failure and hypoparathyroidism. It is indicated for improving various symptoms associated with vitamin D metabolic abnormalities (hypocalcemia, tetani bone pain, bone lesions, etc.) in vitamin D-resistant rickets and osteomalacia.
本発明者等は、その後鋭意研究を続けた結果、１α−ヒ
ドロキシビタミンＤ３類に血圧調節作用のあることを見
出し、本発明を完成した。As a result of continued intensive research, the present inventors discovered that 1α-hydroxyvitamin D3 has a blood pressure regulating effect, and completed the present invention.
即ち本発明は、１α−ヒドロキシビタミンＤ３類の血圧
調節剤に関する。That is, the present invention relates to a blood pressure regulating agent of the 1α-hydroxyvitamin D3 class.
本発明において用いられる工α−ヒドロキンビタミンＤ
３類とは
１α一（ＯＨ）−Ｄ３．
１α，２５− （ＯＨ） ２−Ｄ３，
ｌα．２４Ｓ− （ＯＨ） −Ｄ３，２
１α，２４Ｒ− （ＯＨ） 一Ｄ３，２
１α．２４３．２５− （ＯＨ） ３−Ｄ３．ｌα，２
４Ｒ，２５− （ＯＨ） ３−Ｄ３，１α．２５３．２
６− （ＯＨ） ３−Ｄ３，１α．２５Ｒ，２６−（Ｏ
Ｈ） ３−Ｄ３．ｌα，２５− （ＯＨ） ２−２３−
ＯＸＯ−Ｄ３，１α．２５− （ＯＨ） ２−２４−Ｏ
ＸＯ−Ｄ３，１α． ２５Ｓ， ２６ − （ＯＨ）３
−２３−ＯＸＯ−Ｄ３ ，１α， ２ＳＲ， ２６
（ＯＨ）３−２３−ＯＸＯ−Ｄ３ ，１ ａ ， ２５
Ｓ − （ Ｏ Ｈ ）２−Ｄ３−２６、ｊｊ３３
− １ｘｃｊｏｎｅ ，１ ａ ， ２ＳＲ − （Ｏ
Ｈ）２−Ｄ３−２６， ２３８ − ｌｘｃｌｏｎｅ
，１α一（ＯＨ） −２４．２５，２６．２７ −１
ｒｔｔｓｕｃｒ−２３−ＣＯＯＨ−Ｃ３
などが含まれる。α-hydroquine vitamin D used in the present invention
Type 3 is 1α-(OH)-D3. 1α,25- (OH) 2-D3, lα. 24S- (OH) -D3,2 1α, 24R- (OH) -D3,2 1α. 243.25-(OH)3-D3. lα,2
4R,25-(OH)3-D3,1α. 253.2
6- (OH) 3-D3,1α. 25R,26-(O
H) 3-D3. lα,25- (OH) 2-23-
OXO-D3,1α. 25- (OH) 2-24-O
XO-D3,1α. 25S, 26-(OH)3
-23-OXO-D3, 1α, 2SR, 26
(OH)3-23-OXO-D3,1a,25
S-(OH)2-D3-26, jj33
- 1xcjone, 1 a, 2SR - (O
H) 2-D3-26, 238-lxclone
,1α-(OH) −24.25,26.27 −1
Includes rttsucr-23-COOH-C3 and the like.
コレラノ本物質ハ例エばＵ．Ｓ，ＰＩＨｌ ３６９７５
５９ ，特開昭５１−７６２５２．特開昭５１−７６２
５４， Ｕ．Ｓ．Ｐ＊ｔｅｌ３７４１９９６ ．特開
昭５５−２２６５５．特開昭５５−２２６５６，特開昭
５６−６１３５１， Ａｒｃｈ．Ｂｉｏｃｈｅｍ．Ｂ
ｉｏｐｈ７ｓ．， ２０４，３８７（１９８１），
■．Ｆ．Ｄｅ Ｌｕｃｚ， ビタミンＤ−［その新
しい流れ］，講談社，サイエンテイフイク（１９８２）
などに開示されている。For example, U. S, PIHL 36975
59, Japanese Patent Publication No. 51-76252. Japanese Patent Publication No. 51-762
54, U. S. P*tel3741996. Japanese Patent Publication No. 55-22655. JP-A-55-22656, JP-A-56-61351, Arch. Biochem. B
ioph7s. , 204, 387 (1981),
■． F. De Lucz, Vitamin D-[The new trend], Kodansha, Scientific (1982)
etc. are disclosed.
本発明においては光学異性体のいずれを用いてもよく、
又、二種以上を混合して用いてもよい。In the present invention, any of the optical isomers may be used,
Also, two or more types may be used in combination.
本発明の血圧調節剤は活性成分として上記本物質を含有
して、下記に示す種々の製剤形態にて用いられる。本発
明の血圧調節剤は、経口的、非経口的に投与される。The blood pressure regulating agent of the present invention contains the above substance as an active ingredient and is used in various formulations shown below. The blood pressure regulator of the present invention is administered orally or parenterally.
投与形態としては例えば、圧縮錠剤、被覆錠剤，硬又は
軟弾性ゼラチンカプセル，エチルアルコール溶液，油性
または水性溶液または懸濁液などが用いられる。Examples of dosage forms that can be used include compressed tablets, coated tablets, hard or soft elastic gelatin capsules, ethyl alcohol solutions, oily or aqueous solutions or suspensions.
油性溶液の溶媒としては、植物油例えばヤシ油，トウモ
ロコシ油，綿実油，ココナッツ油．落花生油，魚肝油．
油状エステル例えばポリソルベート８０などを使用する
ことができる。Solvents for oily solutions include vegetable oils such as coconut oil, corn oil, cottonseed oil, coconut oil. Peanut oil, fish liver oil.
Oily esters such as polysorbate 80 can be used.
直腸内投与の場合には坐剤ベース例えばカカオ脂または
そのトリグリセライドなどを含む薬用組成物とすること
ができる。For rectal administration, the pharmaceutical composition may include a suppository base, such as cocoa butter or its triglycerides.
本物質は単位投与形態中、２ｘ １Ｇ’乃至ｌｘ ｔｏ
％、好ましくは２ＸＩＧ−４乃至１％を含有する。The substance can be administered in unit dosage form from 2x 1G' to lx to
%, preferably 2XIG-4 to 1%.
又、投与量は０．１乃至１０’ ｎｌ日／人、好ましく
は ０．５乃至１０３Ｒ／日／人とすることができる。Also, the dosage can be 0.1 to 10'nl day/person, preferably 0.5 to 103R/day/person.
そして、上記量的関係が保持されるように、１日１〜３
回の投与回数となるように調製される。Then, so that the above quantitative relationship is maintained, 1 to 3
It is prepared so that the number of administrations is 1.
以下、実施例により本発明を詳述する。Hereinafter, the present invention will be explained in detail with reference to Examples.
実施例１
血圧調節作用
ヒトの本態性高血圧に最も近似し、高血圧モデル動物と
して優れている自然発症高血圧ラット（Ｓ｝ＩＲ）に対
して、中級脂肪酸のトリグリセライドエステル（以下、
ＭＣＴという）に溶解した本物質を１１１ｌ／ｋｇとな
るよう経口投与した。また、対照群にはＭＣＴのみを経
口投与した。投与前、投与後６時間及び１２時間目に血
圧測定器（ウエダ製作所製、ＵＳＭ−１０５ Ｒ型）を
用いて血圧として尾動脈圧を非観血的に測定した。Example 1 Blood pressure regulating effect Triglyceride esters of intermediate fatty acids (hereinafter referred to as
This substance dissolved in MCT) was orally administered at a dose of 111 l/kg. In addition, MCT alone was orally administered to the control group. Before administration, 6 hours and 12 hours after administration, tail artery pressure was measured non-invasively as blood pressure using a blood pressure measuring device (manufactured by Ueda Seisakusho, USM-105 R type).
結果を下記表−１に示す。The results are shown in Table 1 below.
結果は、各群２０乃至２５週齢のラット５匹の平均値で
示した。The results are shown as the average value of 5 rats aged 20 to 25 weeks in each group.
表
１
なお、ｌα一（ＯＨ）−Ｄ ．１α．２４Ｒ−３
（ＯＨ） −Ｄ ，１α．２５− （ＯＨ） ２−
Ｄ３２３
の経口投与による急性毒性値（ Ｌ Ｄ ５０）はそれ
ぞれ６８０． ２５００＜， ２０００＃／ｋｇであっ
たので、１α−ヒドロキシビタミンＤ３類は血圧調節剤
として有用であることが示された。Table 1 Note that lα-(OH)-D. 1α. 24R-3 (OH) -D ,1α. 25- (OH) 2-
The acute toxicity value (LD50) for oral administration of D323 was 680. 2500<, 2000 #/kg, indicating that 1α-hydroxyvitamin D3 is useful as a blood pressure regulator.
実施例２
１α一（ＯＨ）−Ｄ３をパナセート ８００（日本油脂
製，中級脂肪酸のトリグリセライド）に１０７１９ ７
ｍｌの濃度に溶解し、エカプセル中に１α−（ＯＨ）
−Ｄ３をＩＩｉ９含有するように下記剤皮戊分を加温溶
解し、軟カプセル製造機を用いて常法により軟カプセル
剤を作威した。Example 2 1α-(OH)-D3 was added to Panacet 800 (manufactured by NOF Corporation, intermediate fatty acid triglyceride) 10719 7
1α-(OH) dissolved in Ecapsule to a concentration of ml
-D3 was dissolved by heating to contain IIi9 of the drug, and soft capsules were prepared in a conventional manner using a soft capsule making machine.
剤皮処方例
ゼラチン １０重量部グリセリン
２重量部防腐剤（エチルパラベン）
０．０５重量部チタンホワイト
０．２重量部水 ０．２重量
部（最終形態に於ける重量部）
実施例３
実施例２の１α−（ＯＨ）−Ｄ３に代えて、１α，２５
− （ＯＨ） ２−Ｄ３を用い、以下同様にして１α，
２５− （ＯＨ） ２−Ｄ３をｌカプセル当り１／４１
を含有する軟カプセル剤を得た。Shell formulation example Gelatin 10 parts by weight Glycerin
2 parts by weight preservative (ethylparaben)
0.05 parts by weight titanium white
0.2 parts by weight Water 0.2 parts by weight (parts by weight in final form) Example 3 In place of 1α-(OH)-D3 in Example 2, 1α,25
- (OH) Using 2-D3, 1α,
25- (OH) 2-D3 1/41 per l capsule
Soft capsules containing the following were obtained.
実施例４ 実施例２のｌα一（ＯＨ）−Ｄ３に代えて、１ α． ２４Ｒ− （Ｏ Ｈ） ２ Ｄ３を用い、以下同様 にして工α， ２４Ｒー （Ｏ Ｈ） 一 Ｄ ２３ を１カプセ ル当リエ即を含有する軟カプセル剤を得た。Example 4 In place of lα-(OH)-D3 in Example 2, 1α. 24R- (OH) 2 Using D3, and so on And then α, 24R- (OH) One D 23 1 capsule of Soft capsules containing Le Torie Sochi were obtained.
出７ｉｐｒａ：呉羽化学工業株式会社7ipra: Kureha Chemical Industry Co., Ltd.
Claims (1)
とを特徴とする血圧調節剤。(1) A blood pressure regulator characterized by containing 1α-hydroxyvitamin D_3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24470590A JPH03169817A (en) | 1983-08-02 | 1990-09-14 | Blood pressure regulating agent containing 1alpha-hydroxyvitamin d3 compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14132383A JPS6045516A (en) | 1983-08-02 | 1983-08-02 | Physiologically active agent containing 1alpha- hydroxyvitamin d3 |
| JP24470590A JPH03169817A (en) | 1983-08-02 | 1990-09-14 | Blood pressure regulating agent containing 1alpha-hydroxyvitamin d3 compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14132383A Division JPS6045516A (en) | 1983-08-02 | 1983-08-02 | Physiologically active agent containing 1alpha- hydroxyvitamin d3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03169817A true JPH03169817A (en) | 1991-07-23 |
| JPH054368B2 JPH054368B2 (en) | 1993-01-19 |
Family
ID=26473576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP24470590A Granted JPH03169817A (en) | 1983-08-02 | 1990-09-14 | Blood pressure regulating agent containing 1alpha-hydroxyvitamin d3 compounds |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03169817A (en) |
-
1990
- 1990-09-14 JP JP24470590A patent/JPH03169817A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH054368B2 (en) | 1993-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1968567B1 (en) | Omega 3 fatty acid formulations | |
| JPH07501343A (en) | Oral 1α-hydroxy previtamin D | |
| US20130213851A1 (en) | Omega 3 fatty acid formulations | |
| HUE029572T2 (en) | Treatment of Vitamin D Insufficiency and Deficiency with 25-Hydroxy-D2 and 25-Hydroxy-D3 | |
| JPS5832823A (en) | Cancer eliminating agent | |
| EP3047847A1 (en) | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency | |
| JPH0424325B2 (en) | ||
| US20090143484A1 (en) | Use of garlic oil to increase bioavailability of coenzyme q-10 | |
| JPH0319207B2 (en) | ||
| JPH03169817A (en) | Blood pressure regulating agent containing 1alpha-hydroxyvitamin d3 compounds | |
| JPS60120812A (en) | Remedy for diabetic osteopenia | |
| JPH03169820A (en) | Blood lipid regulating agent containing 1alpha-hydroxyvitamin d3 compounds | |
| JPH03169819A (en) | Antithrombotic agent containing 1alpha-hydroxyvitamin d3 compounds | |
| JPH0319209B2 (en) | ||
| JPH03169818A (en) | Inhibitor of blood platelet agglutination containing 1alpha-hydroxyvitamin d3 compounds | |
| JPS58118516A (en) | Calcium adjusting agent containing 1alpha,25-dihydroxyvitamin d3-26,23-lactone | |
| JPH069406A (en) | Antirachitic agent | |
| RU2150269C1 (en) | Lactobacterium-containing soft capsule for treatment of patient with vagina dysbacteriosis | |
| JPS6011422A (en) | Antimyodystrophic agent | |
| JPS6221330B2 (en) | ||
| JPS6221333B2 (en) | ||
| JPS6342606B2 (en) | ||
| JPS6011419A (en) | Blood pressure controlling agent | |
| JPH0377173B2 (en) | ||
| JPS5965014A (en) | Calcium adjusting agent containing 25-hydroxyvitamin d3-26,23-peroxylactone as active constituent |